Don’t let its sub-$1 billion market cap fool you: Medical technology company Semler Scientific (OTC: SMLR) is seeing explosive growth thanks to its successful QuantaFlo product and its software for physicians. QuantaFlo is quickly becoming the industry standard for peripheral artery disease (PAD) testing in patients, and this is likely just the tip of the iceberg for this promising product. Further, Semler may have more product winners in its pipeline to add even more fuel to the company‘s growth story.
PAD typically affects individuals ages 65 and up, as plaque-clogged arteries decrease blood flow to the legs and feet. If left untreated, PAD can develop into serious problems, including increased risk of heart attacks, stroke, renal artery disease, and the possible limb amputation. Fortunately, PAD can be treated and reversed if caught early enough. Semler estimates that 8 million to 18 million Americans have PAD, and that roughly 75% of those cases go undiagnosed. Clearly this is a serious disease, and Semler is taking the lead in preventative care through QuantaFlo.